News | November 17, 2021
Sluggish exports to cap pharma revenue growth at 9% this fiscal
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
Launching in 2022, its availability will be expanded to the global market
BRIDGE-1 Comprehensive care programme for Type 1 diabetes and to train 400 physicians and benefit over 1000 children
The Indian Pharmacopoeia Commission (IPC) has added 23 new impurities standards and 7 new Indian Pharmacopoeial Reference standards
Forty-two per cent Indian patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described “confusion about what I was supposed to do next” as an important barrier to early and accurate diagnosis
Carestream equipment is highly recommended for its imaging quality
Diabetes has the highest prevalence and comorbidities among all NCD’s in India and it is mostly found among people in the south and east India
The initiative will engage adolescents and youth of India in decisions about their reproductive health
Subscribe To Our Newsletter & Stay Updated
